The CARDS trial: Diabetic patients dealt a winning hand

被引：8

作者：

Armani A. ^{[1
]}

Toth P.P. ^{[1
]}

机构：

[1] Sterling Rock Falls Clinic, Sterling, IL 61081

来源：

Current Atherosclerosis Reports | 2006年 / 8卷 / 5期

关键词：

Atorvastatin; Pravastatin; Statin Therapy; Impaired Fasting Glucose; National Cholesterol Education Program;

D O I：

10.1007/s11883-006-0041-9

中图分类号：

学科分类号：

摘要：

Until recently, the role of statin therapy in diabetic patients without clinical signs or symptoms of coronary heart disease had been inadequately defined. The Collaborative Atorvastatin Diabetes Study (CARDS) is a prospective, randomized, placebo-controlled trial designed to compare the effects of atorvastatin with placebo in preventing primary coronary events in diabetic patients. After a median of only 3.9 years (the study was terminated approximately 2 years early due to the magnitude of benefit attributable to atorvastatin therapy), risk for major cardiovascular events was decreased by 37%, acute coronary heart disease-related events were also reduced by 36%, coronary revascularizations by 31%, and stroke by 48%. Benefit emerged within 1 year of initiating therapy. Copyright © 2006 by Current Science Inc.

引用

页码：429 / 432

页数：3

共 18 条

[1]

Colhoun H.M., Betteridge D.J., Durrington P.N., Et al., Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial, Lancet, 364, pp. 685-696, (2004)

[2]

Colhoun H.M., Thomason M.J., Mackness M.I., Et al., Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes, Diabet Med, 19, pp. 201-211, (2002)

[3]

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel, Arch Intern Med, 148, pp. 36-69, (1988)

[4]

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II), JAMA, 269, pp. 3015-3023, (1993)

[5]

Jones P., Kafonek S., Laurora I., Hunninghake D., Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study), Am J Cardiol, 81, pp. 582-587, (1998)

[6]

Bakker-Arkema R.G., Davidson M.H., Goldstein R.J., Et al., Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia, JAMA, 275, pp. 128-133, (1996)

[7]

MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebo controlled trial, Lancet, 360, pp. 7-22, (2002)

[8]

Collins R., Armitage J., Parish S., Et al., MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial, Lancet, 361, pp. 2005-2016, (2003)

[9]

Pyorala K., Pedersen T.R., Kjekshus J., Et al., Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S), Diabetes Care, 20, pp. 614-620, (1997)

[10]

Haffner S.M., Alexander C.M., Cook T.J., Et al., Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: Subgroup analyses in the Scandinavian Simvastatin Survival Study, Arch Intern Med, 159, pp. 2661-2667, (1999)

← 1 2 →